{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T10:19:05Z","timestamp":1783937945757,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.1016\/j.bone.2006.01.150","type":"journal-article","created":{"date-parts":[[2006,3,8]],"date-time":"2006-03-08T12:31:19Z","timestamp":1141821079000},"page":"S2-S6","source":"Crossref","is-referenced-by-count":88,"special_numbering":"S1","title":["Adherence, patient preference and dosing frequency: Understanding the relationship"],"prefix":"10.1016","volume":"38","author":[{"given":"J.Y.","family":"Reginster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Rabenda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Neuprez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2006.01.150_bib1","first-page":"1","article-title":"Prevention and management of osteoporosis","volume":"921","year":"2003","journal-title":"World Health Organ. Tech. Rep. Ser."},{"key":"10.1016\/j.bone.2006.01.150_bib2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.01.150_bib3","first-page":"1","article-title":"Osteoporosis prevention, diagnosis, and therapy","volume":"17","year":"2000","journal-title":"NIH Consens. Statement"},{"key":"10.1016\/j.bone.2006.01.150_bib4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0002-9343(03)00362-0","article-title":"Early discontinuation of treatment for osteoporosis","volume":"115","author":"Tosteson","year":"2003","journal-title":"Am. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2006.01.150_bib5","first-page":"S529","article-title":"Compliance with alendronate treatment in an osteoporosis clinic","volume":"15","author":"Lombas","year":"2001","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.01.150_bib6","first-page":"1377","article-title":"Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis","volume":"4","author":"Ettinger","year":"1998","journal-title":"Am. J. Manag. Care"},{"key":"10.1016\/j.bone.2006.01.150_bib7","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00198-002-1370-3","article-title":"Tolerability and compliance with risedronate in clinical practice","volume":"14","author":"Hamilton","year":"2003","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.01.150_bib8","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1007\/s00198-004-1818-8","article-title":"Correlation between patient recall of bone densitometry results and subsequent treatment adherence","volume":"16","author":"Pickney","year":"2005","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.bone.2006.01.150_bib9","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.bone.2006.01.150_bib10","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.01.150_bib11","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.01.150_bib12","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.bone.2006.01.150_bib13","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.01.150_bib14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif. Tissue Int."},{"key":"10.1016\/j.bone.2006.01.150_bib15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral daily ibandronate prevents bone loss in early postmenopausal women with osteoporosis","volume":"19","author":"McClung","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.01.150_bib16","first-page":"1","article-title":"Therapeutic equivalence of alendronate 70\u00a0mg once-weekly and alendronate 10\u00a0mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group","volume":"12","author":"Schnitzer","year":"2000","journal-title":"Aging (Milano)"},{"key":"10.1016\/j.bone.2006.01.150_bib17","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"De Groen","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bone.2006.01.150_bib18","doi-asserted-by":"crossref","first-page":"488","DOI":"10.18553\/jmcp.1998.4.5.488","article-title":"Alendronate use among 812 women: prevalence of gastrointestinal complaints, noncompliance with patient instructions, and discontinuation","volume":"4","author":"Ettinger","year":"1998","journal-title":"J. Manag. Care Pharm."},{"key":"10.1016\/j.bone.2006.01.150_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1053\/gast.2000.16517","article-title":"Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women","volume":"119","author":"Lanza","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bone.2006.01.150_bib20","first-page":"408","article-title":"Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: the IMPACT study","volume":"72","author":"Eastell","year":"2003","journal-title":"Calcif. Tissue Int."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2006.01.150_bib21","first-page":"S107","article-title":"Longer-term effectiveness outcomes of non-compliance and non-persistence with daily-regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care","volume":"15","author":"Sebaldt","year":"2004","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.01.150_bib22","article-title":"Adherence rates to bisphosphonate therapy: relationship to bone fractures at 24 months in women with postmenopausal osteoporosis","author":"Siris","year":"2005"},{"key":"10.1016\/j.bone.2006.01.150_bib23","unstructured":"Surgeon General. 2004. Bone health and osteoporosis: a report of the Surgeon General. http:\/\/www.hhs.gov\/surgeongeneral\/library\/bonehealth\/content.html. Accessed 10 August, 2005."},{"issue":"Suppl. 3","key":"10.1016\/j.bone.2006.01.150_bib24","first-page":"S45","article-title":"Persistence and compliance with daily and weekly-administered bisphosphonates for osteoporosis treatment in Germany","volume":"16","author":"Bartl","year":"2005","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.bone.2006.01.150_bib25","first-page":"S513","article-title":"Medication persistence is improved with less frequent dosing of bisphosphonates, but remains inadequate","volume":"50","author":"Ettinger","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2006.01.150_bib26","first-page":"S448","article-title":"Does dosing regimen impact persistence with bisphosphonate therapy among postmenopausal osteoporotic women?","volume":"19","author":"Cramer","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.bone.2006.01.150_bib27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.maturitas.2003.12.012","article-title":"Patients with osteoporosis prefer once weekly to once daily dosing with alendronate","volume":"48","author":"Kendler","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.bone.2006.01.150_bib28","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/S0149-2918(02)80085-6","article-title":"Patient preference for once-weekly alendronate 70\u00a0mg versus once-daily alendronate 10\u00a0mg; a multicenter, randomized, open-label, crossover study","volume":"24","author":"Simon","year":"2002","journal-title":"Clin. Ther."},{"key":"10.1016\/j.bone.2006.01.150_bib29","first-page":"31","article-title":"Women with postmenopausal osteoporosis express a preference for once-monthly versus once-weekly bisphosphonate treatment","volume":"30","author":"Simon","year":"2005","journal-title":"Female Patient"},{"issue":"Suppl. 1","key":"10.1016\/j.bone.2006.01.150_bib30","first-page":"S416","article-title":"BALTO I: women treated for osteoporosis rate preference and convenience for once-monthly ibandronate versus once-weekly alendronate","volume":"20","author":"Emkey","year":"2005","journal-title":"J. Bone Miner. Res."}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328206002237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328206002237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T17:41:58Z","timestamp":1627148518000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328206002237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S8756328206002237"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2006.01.150","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}